Summary
ANTWERP PHARMACIES is a financial institution. The bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €4.3m and a net result of €2.2m. Equity has been growing by about 26% per year since 2019. Its solvency ranks better than 21% of 3,032 sector peers (NACE 64, financial year 2025). The company has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
Source: KBO- Status
- Active since 08-08-2018 Normal situation
- Activity
- Activities of holding companies NACE 64210and 4 others
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 2025
- Establishment unit
- 2.278.443.490 2000 Antwerpen, since 08-08-2018
- Financial year end
- 31 December
- Peppol
- Reachable since 12-01-2026
Board and ownership
Board
- Jeff Roskams Consulting BVDirector · since 18-11-2019
- Darwin NVDirector · since 01-09-2020
Shareholders
- Jeff Roskams Consulting25%· score 902024 annual accounts of Jeff Roskams Consulting
- Holdings
- Shares in 10 companies including APOTHEEK DIRK VAN HERCK and APOTHEEK EUROPA
Financial position
Financial institution: outside the modelBankruptcy probability: sector outside the model
Annual accounts 2025
- Profit
- €2.2m
- ▲ 850%
- Equity
- €4.3m
- ▲ 106%
- Total assets
- €16.9m
- ▲ 3.2%
- Employees on 31-12-2025
- 4
- ▲ 33.3%
Net result +850%: other schema
SignalsneutralLatest accounts filed on timeShow the evidence
Checked score
Outside the general model
Model not applicable to financial institutions
The Checked score measures liquidity, leverage and margins against the norms for trading and manufacturing companies. A bank, insurer or financial holding has a very different balance sheet. Those ratios and the score mean nothing here. So there is no financial strength either.
Bankruptcy probability within 12 months
The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
1 signal.
neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-07-2026, 21 days ahead of the deadline.
NBB · 7 filingsDeviation from the deadline
2025
21 days early
2024
65 days early
2023
55 days early
2022
54 days early
2021
26 days early
2020
60 days early
2019
39 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 46 days before the deadline. In the sector (NACE 64), the median for financial year 2024 was 14 days before the deadline, and 28% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 7 June (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
03-11-2026 today31-12-2026 year end31-07-2027 deadline
Key points
- Positive: Result rose in 2025different schema filed ▲ 850% View
- Positive: 9th largest company by total assets in Sint-Truiden, Finance and insurance sectorin the Checked rankings No. 9 View
- Heads a groupcompanies controlled 11 View
- Positive: Always filed on timeaccounts within the deadline every year 7 years View
- Positive: 7 profitable years in a rowprofit 2025: €2.2m 7 years View
Recent changes
- · Gazette deed Incorporation · Founder
- · Gazette deed Incorporation
Companies linked to ANTWERP PHARMACIES
Comparable companies
These companies have the same main activity as ANTWERP PHARMACIES: activities of holding companies (NACE 64210). They are comparable in size and age: total assets between €11m and €21m, founded between 2016 and 2020.
| Company | Total assets | Turnover |
|---|---|---|
| ANTWERP PHARMACIES Sint-Truiden | €16.9m | €1.2m |
| BALTEAU GROUP Saint-Nicolas | €18.2m | €1.4m |
| Merco Services Merelbeke-Melle | €16.2m | €0.8m |
| ICOMET GROUP Deinze | €15.4m | €1.3m |
| SRW HOLDING Tielt | €19.0m | €1.3m |
| Cagico Izegem | €20.8m | €1.0m |
| Apricusa Meise | €11.2m | €1.7m |
Key facts about ANTWERP PHARMACIES
- What is the company number of ANTWERP PHARMACIES?
- The company number of ANTWERP PHARMACIES is 0700.733.344. The VAT number is the same number with BE in front: BE 0700.733.344.
- Where is ANTWERP PHARMACIES based?
- The registered office is at N.B. de Borchgravestraat 4430, 3800 Sint-Truiden.Company details
- What does ANTWERP PHARMACIES do?
- According to the KBO register, the main activity is activities of holding companies (NACE 64210).
- What is the legal form of ANTWERP PHARMACIES?
- The legal form of ANTWERP PHARMACIES is Private limited company (BV).
- When was ANTWERP PHARMACIES founded?
- ANTWERP PHARMACIES was founded on 08-08-2018.
- Is ANTWERP PHARMACIES still active?
- Yes, ANTWERP PHARMACIES is an active enterprise in the KBO register.
- How many employees does ANTWERP PHARMACIES have?
- ANTWERP PHARMACIES had an average of 4.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does ANTWERP PHARMACIES fall under?
- In its 2025 annual accounts, ANTWERP PHARMACIES states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of ANTWERP PHARMACIES?
- The turnover of ANTWERP PHARMACIES was €1.2m in financial year 2025, according to the filed annual accounts.
- Is ANTWERP PHARMACIES profitable?
- In financial year 2025, ANTWERP PHARMACIES made a profit of €2.2m.
- Where can I find the annual accounts of ANTWERP PHARMACIES?
- ANTWERP PHARMACIES filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ANTWERP PHARMACIES due?
- ANTWERP PHARMACIES must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies See the other companies in the same group.ANTWERP PHARMACIES · 12 companies
See how customers, suppliers and banks see your own company and what to improve first.